OCS-01: A potential paradigm
shift in DME treatment

One of our most advanced product candidates, OCS-01, is in phase 2 clinical development for DME and also for Pain and inflammation following ocular surgery. The Phase 2 trial in DME (DX-211) with 144 patients was successfully completed providing the first proof-of-concept for a topical drug effect on a chronic retinal disease.

OCS-01 has been developed from Oculis’ solubilizing nanoparticle (SNP) technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments and enhances their bioavailability in the relevant eye tissues. If approved in DME, it has the potential to provide a new option for patients.

OCS-01: A potential treatment
for Post-cataract Surgery Inflammation

Because patients undergoing cataract surgery are usually on several medications daily, adding more eye drops can be challenging. A long-acting topical solution such as OCS-01 has the potential of reducing the frequency of the burden of administration to patients.

OCS-02: THE POTENTIAL OF
topical anti-TNF alpha
therapy for ophthalmic
indications

The compound, named OCS-02, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials including two controlled studies under IND. The studies demonstrated a promising profile for treating inflammatory conditions of the anterior segment of the eye including Uveitis and Dry Eye Disease.